Cataract formation and prevention

Expert Opinion on Investigational Drugs

Volumn 13, Issue 6, 2004, Pages 691-701

  Shichi, Hitoshi ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Age related cataract; Mechanisms of cataract formation; Oxidative stress theory; Prevention

Indexed keywords

2 FLUOROSPIRO[FLUORENE 9,4' IMIDAZOLIDINE] 2',5' DIONE; ACETYLSALICYLIC ACID; ADRENALIN; AL 0156; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; BENDAZAC; BETA CAROTENE; CALPASTATIN; CORTICOSTEROID; ESTRADIOL; ESTROGEN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIOTIC AGENT; MYDRIATIC AGENT; NAPHTHALENE; NEOSTIGMINE; PANTETHINE; PARACETAMOL; PILOCARPINE; POLYMYXIN B; PREDNISOLONE; RETINOL; UNINDEXED DRUG; VITAMIN B COMPLEX; XENOBIOTIC AGENT;

AGING; BLINDNESS; CATARACT; CATARACTOGENESIS; CLINICAL TRIAL; CONGENITAL CATARACT; COST CONTROL; DISEASE COURSE; DRUG MEGADOSE; DRUG METABOLISM; HEALTH BEHAVIOR; HUMAN; INCIDENCE; LIFESTYLE; MALNUTRITION; NONHUMAN; OXIDATIVE STRESS; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SMOKING; ULTRAVIOLET RADIATION;

AGING; ANIMALS; CATARACT; HUMANS; OSMOLAR CONCENTRATION; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; SUNLIGHT; ULTRAVIOLET RAYS; XENOBIOTICS;

EID: 3042847638     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.6.691     Document Type: Review

References (149)

1. THYLEFORS B, NEGREL AD, PARARAJASEGARAM R, DADZIE KY: Global data on blindness. Bull. World Health Organ. (1995) 73:115-121.
2. JAVITT JC: Who does cataract surgery in the United States? Arch. Ophthalmol. (1993) 111:1329.
3. JOSHI N, CONSTABLE PH, MARGOLIS TP, HOYL CS, LEONARD TJ: Bilateral angle closure glaucoma and accelerated cataract in a patient with AIDS. Br. J. Ophthalmol. (1994) 78:656-657.
4. SCHNAUDIGEL OE, GUMBEL H, RICHTER R, SUBKLEW R, GARWEG T: Ophthalmologic manifestations in early and late stages of AIDS. Ophthalmologe (1994) 91:668-670.
5. JAANUS SD: Drug-related cataract. Optom. Clin. (1991) 1:143-157.
6. HODGE W, WHITCHER JP, SATARIANO W: Risk factors for age-related cataracts. Epidemiol. Rev. (1995) 17:336-346.
7. BROWN NA, BRON AJ, HARDING JJ, DEWAR HM: Nutrition supplements and the eye. Eye (1998) 12:127-133.
8. HARDING JJ: Can drugs or micronutrients prevent cataract? Drugs Aging (2001) 18:473-486.
9. CONGDON NG: Prevention strategies for age related cataract: Present limitations and future possibilities. Br. J. Ophthalmol. (2001)85(5):516-520.
10. ZIGMAN S, PAXHIA T, McDANIEL T, LOU MF, YU NT: Effect of chronic near-ultraviolet radiation on the gray squirrel lens in vivo. Invest. Ophthalmol. Vis. Sci. (1991) 32:1723-1732.
11. HIGHTOWER KR: A review of the evidence that ultraviolet radiation is a risk factor in cataractogenesis. Doc. Ophthalmol. (1995) 88:205-220.
12. BALASUBRAMANIAN D: Ultraviolet radiation and cataract. J. Ocular Pharmacol. Therapeut. (2000) 16:285-297.
13. ROBERTS J, FINLEY EL, PATAT SA, SCHEY KL: Photooxidation of lens proteins with xanthurenic add: a putative chromophore for cataractogenesis. Photochem. Photobiol. (2001) 74:740-744.
14. WEINREB O, DOVRAT A, DUNIA I, BENEDETTI EL, BLOEMENDAL H: UV-A-related alterations of young and adult lens water-insoluble α-crystallin, plasma membranous and cytoskeletal proteins. Eur. J. Biochem. (2001) 268:536-543.
15. DE JONG WW, LEUNISSEN JAM, VOORTER CEM: Evolution of the α-crystallin/small heat-shock protein family. Mol. Biol. Evol. (1993) 10:103-126.
16. HORWITZ J: α-Crystallin can function as a molecular chaperone. Proc. Natl. Acad. Sci. USA (1992) 89:10449-10453.
17. SLINEY DH: Physical factors in cataractogenesis: Ambient ultraviolet radiation and temperature. Invest. Ophthalmol. Vis. Sci. (1986) 27:781-790.
18. AYALA MN, MICHAEL R, SODERBERG PG: In vivo cataract after repeated exposure to ultraviolet radiation. Exp. Eye Res. (2000) 70:451-456.
19. TAYLOR HR, WEST SK, ROSENTHAL FS et al.: Effect of ultraviolet radiation on cataract formation. N. Engl. J. Med. (1988) 320:1285-1286.
20. WEST SK, DUNCAN DD, MUNOZ B et al.: Sunlight exposure and risk of lens opacities in a population-based study. JAMA (1998) 280:714-718.
21. McCARTY CA, NANJAN MB, TAYLOR HR: Attributable risk estimates for cataract to prioritize medical and public health action. Invest. Ophthalmol. Vis. Sci. (2000) 41:3720-3725.
22. BOCHOW TW, WEST SK, AZAR A, MUNOZ B, SOMMER A, TAYLOR HR: Ultraviolet light exposure and risk of posterior subcapsular cataracts. Arch. Ophthalmol. (1989) 107:369-372.
23. FRANCIS P, CHUNG JJ, YASUI M et al.: Functional impairment of lens aquaporin in two families with dominantly inherited cataracts. Human Mol. Genet. (2000) 9:2329-2334.
24. NAKANO K, YAMAMOTO S, KATSUKAKE G, OGAWA H, NAKAJIMA A, TAKANO E: Hereditary cataract in mice. Jpn. J. Clin. Ophthalmol. (1960) 14:196.
25. IWATA S, KINOSHITA JH: Mechanism of development of hereditary cataract in mice. Invest. Ophthalmol. 10:504-512.
26. KUWABARA T, KINOSHITA JH, COGAN DG: Electron microscopic study of galactose-induced cataract. Invest. Ophthalmol. (1969) 8:133-149.
27. ROBISON WG, HOULDER N, KINOSHITA JH: The role of lens epithelium in sugar cataract formation. Exp. Eye Res. (1990) 50:641-646.
28. KINOSHITA J: A thirty year journey in the polyol pathway. Exp. Eye Res. (1990) 50:567-573.
29. VAN HEYNINGEN R: Sorbitol pathway-reminiscences. Exp. Eye Res. (1990) 50:583-588.
30. CARPER D, NISHIMURA C, SHINOHARA T et al.: Aldose reductase and rho-crystallin belong to the same protein superfamily as aldehyde reductase. FEBS Lett. (1987) 220:209-213.
31. LUDVIGSON MA, SORENSON RL: Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes (1980) 29:450-459.
32. NISHIMURA C, AKAGI Y, ROBISON WG, KADOR PF, KINOSHITA JH: Increased aldose reductase activity in galactosemic lens. In: Polyol Pathway and Role in Diabetic Complications. N Sakamoto, JH Kinoshita, PF Kador, N Hotta (Eds), Elsevier, New York (1988):182-188.
33. STITT AW: Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J. Ophthalmol. (2001) 85:746-753.
34. KONERU PB, LIEN EJ, KODA RT: Oculotoxicities of systemically administered drugs. J. Ocular Pharmacol. (1986) 2:385-404.
35. HOLLWICH F, BOATENG A, KOLCK B: Toxic cataract. In: Cataract and Abnormalities of the Lens. JG Bellows (Ed.), Grune & Stratton, New York (1975):230-243.
36. CHENG Q, ROBISON WG, ZIGLER JS: Geranylgeranyl pyrophosphate counteracts the cataractogenic effect of lovastatin on cultured rat lenses. Exp. Eye Res. (2002) 75:603-609.
37. CENEDELLA RJ, KUSZAK JR, AL-GHOUL KJ, QIN S, SEXTON PS: Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: thom rats. J. Lipid Res. (2003) 44:198-211.
38. SHICHI H: Biotransformation and drug metabolism. In: Pharmacology of the Eye. ML Sears (Ed.), Springer-Verlag, Berlin (1984):117-148.
39. O'BRIEN PJ: Molecular mechanisms of quinone cytotoxicity. Chem. Biol. Interact. (1991) 80:1-41.
40. SHICHI H, TANAKA M, JENSEN NM, NEBERT DW: Genetic differences in cataract and other ocular abnormalities induced by paracetamol and naphthalene. Pharmacology (1980) 20:229-241.
41. WELLS P, WILSON B, LUBEK BM: In vivo murine studies on the biochemical mechanism of naphthalene cataractogenesis. Toxicol. Appl. Pharmacol. (1989) 99:466-473.
42. XU GT, ZIGLER JS, LOU MF: The possible mechanism of naphthalene cataract in rat and its prevention by an aldolase reductase inhibitor (ALI 1576). Exp. Eye Res. (1992) 54:63-72.
43. BOLTON JL, TRUSH MA, PENNING TM, DRYHURST G, MONKS TJ: Role of quinones in toxicity. Chem. Res. Toxicol. (2000) 13:135-160.
44. SUGIYAMA K, WANG TL, SIMPSON JT, RODRIGUEZ L, KADOR P, SATO S: Aldose reductase catalyzes the oxidation of naphthalene-1, 2-dihydrodiol for the formation of orthonaphthoquinone. Drug Met. Dispos. (1999) 27:60-67.
45. RAO PV, ZIGLER JS: Zeta-crystallin from guinea-pig lens is capable of functioning catalytically as an oxidoreductase. Arch. Biochem. Biophys. (1991) 284:181-185.
46. BAZZI MD: Interaction of camel lens zeta-crystallin with quinones: Portrait of a substrate by fluorescence spectroscopy. Arch. Biochem. Biophys. (2001) 395:185-190.
47. SHICHI H, GAASTERLAND DE, NEBERT DW: The Ah locus: genetic differences in susceptibility to cataracts induced by acetaminophen. Science (1978) 200:539-541.
48. LUBEK BM, AVARIA M, BASU PK, WELLS PG: Pharmacological studies on the in vivo cataractogenicity of acetaminophen in mice and rabbits. Found. Appl. Toxicol. (1988) 10:596-606.
49. RAUCY JL, LASKER JM, LIEBER CS, BLACK M: Acetaminophen activation by human liver cytochromes P4502 E1 and P450 1A2. Arch. Biochem. Biophys. (1989) 271:270-283.
50. PATTEN CJ, THOMAS PE, GUY RL et al.: Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. (1993) 6:511-518.
51. THUMMEL KE, LEE CA, KUNZE KL, NELSON SD, SLATTERY JT: Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP 3A4. Biochem. Pharmacol. (1993) 45:1563-1569.
52. BESSEMS JGM, VERMEULEN NPE: Paracetamol (acetaminophen)-induced toxicity: Molecular and biochemical mechanisms, analogues and approaches. Crit. Rev. Toxicol. (2001) 31:55-138.
53. ZHAO C, SHICHI H: Histological study on the possible mechanism of acetaminophen cataractogenesis in mouse eye. Exp. Mol. Pathol. (1995) 63:118-128.
54. QIAN W, SHICHI H: Cataract formation by a semiquinone metabolite of acetaminophen in mice. Exp. Eye Res. (2000) 71:567-574.
55. ZHAO C, XIONG Y, SHICHI H: Acetaminophen cytotoxicity in mouse eye: mitochondria in anterior tissues are the primary target. J. Ocular Pharmacol. Therapeut. (1997) 13:269-274.
56. MATHUR P, PESHENKO IV, SHICHI H: Cellular events preceding acetaminophen cataractogenesis studied by confocal fluorescence microscopy. J. Ocular Pharmacol. Therapeut. (2003) 19:483-492.
57. 2+ release and calpain activation. J. Ocular Pharmacol. Therapeut. (2001) 17:383-392.
58. MARTYNKINA LP, QIAN W, SHICHI H: Naphthoquinone-induced cataract in mice: mitochondrial change and prevention by superoxide dismutase. J. Ocular Pharmacol.Therapeut. (2002) 18:231-239.
59. WALLACE KB, STARKOV AA: Mitochondrial targets of drug toxicity. Ann. Rev. Pharmacol. Toxicol. (2000) 40:353-388.
60. SPECTOR A: Oxidative stress-induced cataract: mechanism of action. FASEB J. (1995) 9:1173-1182.
61. REES JR, PIRIE A: Possible reactions of 1, 2-naphthoquinone in the eye. Biochem. J. (1967) 102:853-863.
62. SATO S, SUGIYAMA K, LEE YS, KADOR PK: Prevention of naphthalene-1, 2-dihydrodiol-induced lens protein modifications by structurally diverse aldose reductase inhibitors. Exp. Eye Res. (1999) 68:601-608.
63. CHRISTEN WG, GLYNN RJ, AJANI UA et al.: Smoking cessation and risk of age-related cataract in man. JAMA (2000) 284:713-716.
64. BLACK RL, OGLASBY R, VON SALLMAN L, BUNIN J: Posterior subcapsular cataract induced by corticoids in patients with rheumatoid arthritis. JAMA (1960) 174:166-171.
65. CUMMING RG, MITCHEL P, LEEDER SR: Use of inhaled corticosterods and the risk of cataracts. N. Engl. J. Med. (1997) 337:8-14.
66. DERBY L, MAIER WC: Risk of cataract among users of intranasal corticosteroids. J. Allergy Clin. Immunol. (2000) 105:912-916.
67. MANABE S, BUCALA R, CERAMI A: Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J. Clin. Invest. (1984) 74:1803-1810.
68. BUCALA R, GALLATI M, MANABE S, COTLIER E, CERAMI A: Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp. Eye Res. (1985) 40:853-863.
69. NISHIGORI H, LEE JW, YAMAUCHI Y, MARUYAMA K, IWATSURU M: Analysis of glucose levels during glucocorticoid-induced cataract formation in chick embryo. Invest. Ophthalmol. Vis. Sci. (1987) 28:168-174.
70. NISHIGORI H: Steroid (glucocorticoid)-induced cataract. Nippon Hakunaisho Gakkai-shi. (1991) 11:5-13.
71. HAMMOND CJ, DUNCAN D, SNIEDER H et al.: The heritability of age-related cortical cataract: The twin eye study. Invest. Ophthalmol. Vis. Sci. (2001) 42:601-605.
72. LITT M, KRAMER P, LAMORTICELLA DM, MURPHY W, LOVRIEN FW, WELEBER RG: Autosomal dominant congenital cataract associated with a missense mutation in the human α-crystallin gene CRYAA. Human Mol. Genet. (1998) 7:471-474.
73. GILL D, KLOSE R, MUNIER FL et al.: Genetic heterogeneity of the Coppock-like cataract: a mutation in CRYBB2 on chromosome 22q11.2. Invest. Ophthalmol. Vis. Sci. (2000) 41:159-165.
74. FU L, LIANG JN: Alteration of protein-protein interactions of congenital cataract crystallin mutants. Invest. Ophthalmol. Vis. Sci. (2003) 44:1155-1159.
75. HAIDER NB, IKEDA A, NAGGERT JK, NISHINA PM: Genetic modifiers of vision and hearing. Human Mol. Genetics (2002) 11:1195-1206.
76. GONG X, AGOPIAN K, KUMAR NM, GILULA NB: Genetic factors influence cataract formation in α-3 connexin knockout mice. Dev. Genet. (1999) 24:27-32.
77. MAEDA YY, FUNATA N, TAKAHAMA S, SUGATA Y, YONEKAWA H: Two interactive genes responsible for a new inherited cataract (RCT) in the mouse. Mamm. Genome (2001) 12:278-283.
78. IONIDES A, FRANCIS P, BERRY V, MACKAY D, BHATTACHARYA S, SHIELDS A et al.: Clinical and genetic heterogeneity in autosomal dominant congenital cataract. Br. J. Ophthalmol. (1999) 83:802-808.
79. CAMPAGNOLI MF, PIMAZZONI R, BOSIO S, ZECCHINA G, DEGOBBI M, BOSSO P et al.: Onset of cataract in early infancy associated with 32G→C transition in the iron responsive element of L-ferritin. Eur. J. Pediatr. (2002) 161:499-502.
80. OKANO Y, ASADA M, FUJIMOTO A et al.: A genetic factor for age-related cataract: Identification and characterization of a novel galactokinase variant, 'Osaka,' in Asians. Am. J. Hum. Genet. (2001) 68:1036-1042.
81. MARAINI G, HEJTMANCIK JF, SHIELDS A et al.: Galactokinase gene mutations and age-related cataract. Lack of association in an Italian population. Mol. Vis. (2003) 9:397-400.
82. SEKINE Y, HOMMURA S, HARADA S: Frequency of glutathione-S-transferase 1 gene deletion and possible correlation with cataract formation. Exp. Eye Res. (1995) 60:159-163.
83. TOMAREV SI, ZINOVIEVA RD: Squid major lens polypeptides are homologous to glutathione-S-transferase subunit. Nature (1988) 336:86-88.
84. TOMAREV SI, ZINOVIEVA RD, PIATIGORSKY J: Crystallins of octopus lens. J. Biol. Chem. (1991) 226:24226-24231.
85. KLEIN BE, KLEIN R, LINTON KL: Prevalance of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology (1992) 99:546-552.
86. MITCHELL P, CUMMING RG, ATTEBO K, PANCHAPAKESAN J: Prevalance of cataract in Australia: the Blue Mountains eye study. Ophthalmology (1997) 104:581-588.
87. DEANE JS, HALL AB, THOMPSON JR, ROSENTHAL AR: Prevalence of lenticular abnormalities in a population-based study: Oxford clinical cataract grading in the Melton Eye study. Ophthalmic Epidemiol. (1997) 4:195-206.
88. HILLER R, SPERDUTO RD, EDERER F: Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am. J. Epidemiol. (1986) 124:916-925.
89. WEST SK, MUNOZ B, SCHEIN OD, DUNCAN DD, RUBIN GS: Racial differences in lens opacities: the Salisbury Eye Evaluation (SEE) project. Am. J. Epidemiol. (1998) 148:1033-1039.
90. HAMMOND CJ, DUNCAN D, SNIEDER H et al.: The heritability of age-related cortical cataract: The twin eye study. Invest. Ophthalmol. Vis. Sci. (2001) 42:601-605.
91. BOSIA F, GRATTAGLIANO I, VENDEMIALE G, MICELLI-FERRARI T, ALTOMARE E: Protein oxidation and lens opacity in humans. Invest. Ophthalmol. Vis. Sci. (2000) 41:2461-2465.
92. BORCHMAN D, YAPPERT MC: Age-related lipid oxidation in human lenses. Invest. Ophthalmol. Vis. Sci. (1998) 39:1053-1058.
93. ROSE R, RICHER S, BODE A: Ocular oxidants and antioxidant protection. Proc. Soc. Exp. Biol. Med. (1998) 217:397-407.
94. PIRIE A: Glutathione peroxidase in lens and a source of hydrogen peroxide in aqueous humor. Biochem. J. (1965) 96:244-253.
95. 2 in aqueous humor. Exp. Eye Res. (1984) 38:87-93.
96. HALLIWELL B, CLEMENT MV, LONG LH: Hydrogen peroxide in the human body. FEBS Lett. (2000) 486:10-13.
97. McGAHAN MC, FLEISHER LN: A micromethod for the determination of iron and total iron-binding capacity in intraocular fluids and plasma using electrothermal atomic absorption spectroscopy. Anal. Biochem. (1986) 156:397-402.
98. TAKIKAWA O, LITTLEJOHN TK, TRUSCOTT RJW: Indoleamine 2, 3-dioxygenase in the human lens, the first enzyme in the synthesis of UV filters. Exp. Eye Res. (2001) 72:271-277.
99. ITO S: Reexamination of the structure of eumelanin. Biochim. Biophys. Acta (1986) 883:155-161.
100. LARSSON BS: Interaction between chemicals and melanin. Pigment Cell Res. (1993) 6:127-133.
101. CUMMING RG, MITCHELL P: Alcohol, smoking, and cataract: The Blue Mountains Eye Study. Arch. Ophthalmol. (1997) 115:1296-1303.
102. BENEDEK GB: Cataract as a protein condensation disease: The Procter Lecture. Invest. Ophthalmol. Vis. Sci. (1997) 38:1911-1921.
103. SASO L, SILVESTRINI B: Antidenaturant drugs for cataract and other condensation diseases. Med. Hypotheses (2001) 56:114-120.
104. COTLIER E, SHARMA YR: Aspirin and senile cataracts in rheumatoid arthritis. Lancet (1981) 1:338-339.
105. COTLIER E, SHARMA YR, NIVEN T, BRESCIAM: Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. Am. J. Med. (1983) 74:83-90.
106. CHRISTEN WG, AJANI UA, SCHAUMBERG DA, GLYNN RJ, MANSON JE, HENNEKENS CH: Aspirin use and risk of cataract in posttrial follow-up of physicians' health study I. Arch. Ophthalmol. (2001) 119:405-412.
107. HASAN A, SMITH JB, QIN W, SMITH DL: The reaction of bovine lens αA-crystallin with aspirin. Exp. Eye Res. (1993) 57:29-35.
108. BENEDEK GB, PANDE J, THURSTON GM, CLARK JI: Theoretical and experimental basis for the inhibition of cataract. Progs. Retinal Eye Res. (1999) 18:391-402.
109. KUZNIARZ M, MITCHELL P, CUMMING RG, FLOOD VM: Use of vitamin supplements and cataract: The Blue Mountain Eye Study. Am. J. Ophthalmol. (2001) 132:19-26.
110. ARED Report No. 9: A randomized placebo-controlled clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss. Arch. Ophthalmol. (2001) 119:1439-1452.
111. VAN DER POLS JC: A possible role for vitamin C in age-related cataract. Proc. Nutr. Soc. (1999) 58:295-301.
112. CHENG R, LIN B, LEE KW, ORTWERTH BJ: Similarity of the yellow chromophores isolated from human cataracts with those from ascorbic acid-modified calf lens proteins: evidence for ascorbic acid glycation during cataract formation. Biochim. Biophys. Acta (2001) 1537:14-26.
113. KLEIN BE, KLEIN R, RITTER LL: Is there evidence of an estrogen effect on age-related lens opacities? Arch. Ophthalmol. (1994) 112:85-91.
114. CUMMING R, MITCHELL P: Hormone replacement therapy, reproductive factors, and cataract: the Blue Mountain eye study. Am. J. Epidemiol. (1997) 145:242-249.
115. BIGBY R, CARDENAS H, CAPERELL-GRANT A, GRUBBS CJ: Protective effects of estrogen in a rat model of age-related cataracts. Proc. Natl. Acad. Sci. USA (1999) 96:9328-9332.
116. KIUCHI K, YOSHIZAWA K, MORIGUCHI K, TSUBURA A: Rapid induction of cataract by a single intraperitoneal administration of N-methyl-N-nitrosourea in 15-day-old-Sprague-Dawley (Jcl:SD) rats. Exp. Toxic. Pathol. (2002) 54:181-186.
117. YABE-NISHIMURA C: Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. (1998) 50:21-33.
118. LOU MF, XU GT, ZIGLER S, YORK B: Inhibition of naphthalene cataract in rats by aldose reductase inhibitors. Curr. Eye Res. (1996) 15:423-432.
119. HIGHTOWER KR: Cytotoxic effects of internal calcium on lens physiology: a review. Curr. Eye Res. (1985) 4:453-459.
120. ANDERSSON M, SJOSTRAND J, ANDERSSON AK, ANDERSEN B, KARLSSON JO: Calpains in lens epithelium from patient with cataract. Exp. Eye Res. (1996) 59:359-364.
121. MATSUSHIMA H, DAVID LL, HIRAOKA T, CLARK JI: Loss of cytoskeletal proteins and lens cell opacification in the selenite cataract model. Exp. Eye Res. (1997) 64:387-395.
122. KILLIC F, TREVITHICK JR: Modeling cortical cataractogenesis. XXIX. Calpain proteolysis of lens fodrin in cataract. Biochem. Mol. Biol. Intl. (1998) 45:963-978.
123. SCHEY KL, FOWLER JG, SHEARER TR, DAVID L: Modifications to rat lens major intrinsic protein in selenite-induced cataract. Invest. Ophthalmol. Vis. Sci. (1999) 40:657-667.
124. TAMADA Y, FUKIAGE C, MIZUTANI K et al.: Calpain inhibitor, SJA 6017, reduces the rate of formation of selenite cataract in rats. Curr. Eye Res. (2001) 22:280-285.
125. TAKEUCHI N, ITO H, NAMIKI K, KAMEI A: Effect of calpain on hereditary cataractous rat, ICR/f. Biol. Pharm. Bull. (2001) 24:1246-1251.
126. MATHUR P, GUPTA S, WEGENER AR et al.: Comparison of various calpain inhibitors in reduction of light scattering in precipitation and nuclear cataract in vitro. Curr. Eye Res. (2000) 21:926-933.
127. YOSHIDA H, MURACHI T, TSUKAHARA I: Distribution of calpain I, calpain II, and calpastatin in bovine lens. Invest. Ophthalmol. Vis. Sci. (1985) 26:953-956.
128. AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP: A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss. Arch. Ophthalmol. (2001) 119:1439-1452.
129. CHAKARAPANI B, YEDAVALLY S, LEVERENZ V, GIBLIN FJ, REDDY VN: Simultaneous measurement of reduced and oxidized glutathione in human aqueous humor and cataracts by electrochemical detection. Ophthalmic Res. (1995) 27(Suppl. 1):69-77.
130. KASUYA M, ITOI M, KOBAYASHI S, SUNAGA S, SUZUKI KT: Changes in glutathione and taurine concentrations in lenses of rat eyes induced by galactose-cataract formation or ageing. Exp. Eye Res. (1992) 54:49-53.
131. HIRAOKA T, CLARK JI, LI XY, THURSTON GM: Effect of selected anti-cataract agents on opacification in the selenite cataract model. Exp. Eye Res. (1996) 62:11-19.
132. HEIM KE, TAGLIAFERRO AR, BOBILYA DJ: Flavonoid antioxidants: chemistry, metabolism and structure-activity relationship. J. Nutrit. Biochem. (2002) 13:572-584.
133. ORHAN H, MAROL S, HEPSEN I, SAHIN G: Effects of some probable antioxidants on selenite-induced cataract formation and oxidative stress-related parameters in rats. Toxicology (1999) 139:219-232.
134. 2 insult. Exp. Eye Res. (2003) 76:49-59.
135. SOHAL RS, MOCKETT RJ, ORR WC: Mechanisms of aging: an appraisal of the oxidative stress hypothesis. Free Rad. Biol. Med. (2002) 33:575-586.
136. WEI YH, LEE HC: Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp. Biol. Med. (2002) 227:671-682.
137. MANDAVILLI B, SANTOS J, VANHUTEN B: Mitochondrial DNA repair and aging. Mutation Res. (2002) 509:127-151.
138. BOVERIS A, CADENAS E: Mitochondrial production of hydrogen peroxide regulation by nitric oxide and the role of ubisemiquinone. IUBMB Life (2000) 50:245-250.
139. SOHAL RS, WEINDRUCH R: Oxidative stress, caloric restriction, and aging. Science (1996) 273:59-63.
140. WALLACE DC: Mitochondrial DNA sequence variation in human evolution and disease. Proc. Natl. Acad. Sci. USA (1994) 91:8739-8746.
141. RICHTER C, PARK JW, AMES BN: Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. USA (1988) 85:6465-6467.
142. BEHNDIG A, SVENSSON B, MARKLUND SL, KARLSSON K: Superoxide dismutase isozymes in the human eye. Invest. Ophthalmol. Vis. Sci. (1998) 39:471-475.
143. REDDY VN: Glutathione and its function in the lens - an overview. Exp. Eye Res. (1990) 50:771-778.
144. ALLEN JA, COOMBS MM: Covalent binding of polycyclic aromatic compounds to mitochondrial and nuclear DNA. Nature (1980) 287:244-245.
145. ADACHI K, FUJIURA Y, MARUMI F et al.: A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem. Biophys. Res. Commun. (1993) 195:945-951.
146. LIANG FQ, GODLEY BF: Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: a possible mechanism for RPE aging and age-related macular degeneration. Exp. Eye Res. (2003) 76:397-403.
147. LANE MA, INGRAM DK, ROTH GS: The serious search for an anti-aging pill. Sci. Am. (2002) 287:36-41.
148. GONG X, SHANG F, OBIN M, PALMER H, SCROFANO MM, JAHNGEN-HODGE J: Antioxidant enzyme activities in lens, liver and kidney of calorie restricted Emory mice. Mech. Ageing Develop. (1997) 99:181-192.
149. ZIGLER JS: Animal models for the study of maturity-onset and hereditary cataract. Exp. Eye Res. (1990) 50:651-657.